ENTA management strikes as being very shrewd and thorough in regards to cash deployment, they might not find a better opportunity then to use it here. I would have to imagine they are well aware of OCRX and its potential in the liver disease space but I do agree a deal is less likely simply because well deals in general are less likely :)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.